Skip to main content
Premium Trial:

Request an Annual Quote

Nine New RNAi-Related Patent Applications Published By US Patent Office

Premium

Title: Methods and Kits for Synthesis of siRNA Expression Cassettes. Number: 20040091918. Filed: July 31, 2003. Lead Inventor: John Rossi, Beckman Research Institute.

The patent application, its abstract states, covers “amplification-based methods and kits for rapidly producing siRNA expression cassettes [and] methods for expressing amplified siRNA expression cassettes in cells.”

The application specifically claims an amplification method comprising “treating one strand of a double-stranded promoter sequence, in an amplified reaction mixture, with an oligonucleotide primer [that] is complementary to the 5’ end of the promoter sequence.”

The method then calls for “treating the other strand of the promoter sequence, in the amplification reaction mixture, with a second oligonucleotide primer [that] is complementary to the 3’ end of the promoter sequence, wherein the second primer comprises one or more sequences [that] are complementary to a sequence encoding a sense and/or antisense sequence of an siRNA molecule, along with one or both of a loop sequence and a terminator sequence.”

Finally, the amplification methods requires “treating the amplification reaction mixture of [the first two] steps … in an amplification reaction at a temperature for annealing and extending said primers on the promoter sequence and at a temperature for denaturing the extension products to provide an amplified product comprising the promoter, one or more sequences encoding the sense and/or antisense sequence of the siRNA molecule, and one or both of the loop sequence and the terminator sequence, and wherein the [first and third steps] are repeated [in] a sufficient number of times to amplify the promoter-containing siRNA expression cassette.”


Title: Modulation of G Protein-Coupled Receptor RE2 Expression. Number: 20040091871. Filed: Nov. 11, 2002. Lead Inventor: Ming-Yi Chiang, Isis Pharmaceuticals.

According to the patent application’s abstract, the invention comprises “compounds, compositions, and methods … for modulating the expression of G protein-coupled receptor RE2. The compositions comprises oligonucleotides targeted to nucleic acid encoding [GPCR] RE2.

“Methods of using these compound for modulation of [GPCR] RE2 expression and for diagnosis and treatment of disease,” including a neuroendocrine disorder, “associated with expression of [GPCR] RE2 are provided,” it adds.


Title: Compositions and Methods for Inhibiting Viral Replication. Number: 20040091457. Filed: March 7, 2003. Lead Inventor: Matthias John, Ribopharma (Alnylam Pharmaceuticals).

The patent application, its abstract states, covers “a double-stranded ribonucleic acid having a nucleotide sequence ... less than 30 nucleotides in length and [that] is substantially identical to at least part of a 3’-untranslated region of a + strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA.”

It adds that the compositions can be used to treat “infections and diseases caused by the replication or activity of the + strand RNA virus, as well as methods for inhibiting viral replication.”


Title: Modulation of ADAM9 Expression. Number: 20040092466. Filed: Nov. 11, 2002. Lead Inventor: Frank Bennett, Isis Pharmaceuticals.

The patent application, states its abstract, covers “compounds, compositions, and methods … for modulating the expression of ADAM9. These compositions comprise oligonucleotides targeted to nucleic acid encoding ADAM9.”

Also covered are “methods of using these compounds for [the] modulation of ADAM9 expression and for diagnosis and treatment of disease,” including Alzheimer’s disease, “associated with expression of ADAM9.”


Title: Modulation of Huntingtin Interacting Protein 1 Expression. Number: 20040092465. Filed: Nov. 11, 2002. Lead Inventor: Kenneth Dobie, Isis Pharmaceuticals.

The invention, states the patent application’s abstract, covers “compounds, compositions, and methods … for modulating the expression of huntingtin interacting protein 1. These compositions comprise oligonucleotides targeted to nucleic acid encoding huntingtin interacting protein 1.”

Also covered are use of the compounds for the “modulation of huntingtin interacting protein 1 expression and for diagnosis and treatment of disease[s],” including ones that involve disregulation of cellular apoptosis “associated with expression of huntingtin interacting protein 1.”


Editor's Note:

The US Patent and Trademark Office also has published patent applications numbered 20040092464, 20040092463, 20040092462, and 20040092461. These are all assigned to Isis Pharmaceuticals and cover the use of oligonucleotide compositions that modulate the expression of mitogen-activated protein kinase kinase kinase 11, PIM-1, endothelial differentiation gene 2, and phosphodiesterase 1B, respectively.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.